3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
2
Conditions
Carcinoma, Non-Small-Cell Lung
367
Ovarian Neoplasms
99
Lung Neoplasms
98
Neoplasms
84
Small Cell Lung Carcinoma
71
Breast Neoplasms
59
Neoplasm Metastasis
49
Triple Negative Breast Neoplasms
46
Parkinson Disease 4, Autosomal Dominant Lewy Body
41
Fallopian Tube Neoplasms
38
Squamous Cell Carcinoma of Head and Neck
33
Endometrial Neoplasms
30
Carcinoma
30
Uterine Cervical Neoplasms
28
Colorectal Neoplasms
24
Carcinoma, Ovarian Epithelial
23
Head and Neck Neoplasms
19
Carcinoma, Transitional Cell
18
Urinary Bladder Neoplasms
17
Advanced Solid Tumors
17
Recurrence
15
Melanoma
14
Stomach Neoplasms
13
Peritoneal Neoplasms
13
Pancreatic Neoplasms
12
Adenocarcinoma
11
Lung Diseases
9
Glioblastoma
9
Carcinoma, Squamous Cell
9
Thoracic Neoplasms
8
Interventions
Paclitaxel
3
liposomal doxorubicin
2
Carboplatin
2
1-dodecylpyridoxal
2
pembrolizumab
1
Gemcitabine
1
EP-100 membrane-disrupting peptide
1
Bevacizumab
1
AC 7700
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Ovarian Cancer Recurrent
×
Carboplatin
×
Clear all
NCT06843447
2026-05-26
MK-5909-003
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
460 enrolled
NCT01332656
2015-12-21
OPSALIN
Sanofi
Phase 2
Completed
154 enrolled